Figure 5
From: CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance
CD117 activation by SCF stimulates aggressiveness. (A) Tumor microarrays from prostate cancer patients were stained for phosphorylated (p) CD117. The number of positive cells per core were counted as mean ± SEM (n = 5–20) and separated by Gleason score. (B–D) Sorted C4-2 cells were treated with 50 ng/mL stem cell factor (SCF) to activate CD117. (B) Proliferation was assessed by live-cell imaging and represented as mean percentage confluence ± SEM (n = 12). (C) Chemotaxis through pores towards SCF was measured by live-cell imaging and represented as mean number of cells migrated to the initial numbers seeded ± SEM (n = 8). (D) Gene expression of Oct4 and Sox2 were measured after SCF treatment and represented as mean fold change ± SEM (n = 4). *Represents p < 0.05, **represents p < 0.01, and ***represents p < 0.005 by one-way ANOVA.
